Biblio

33557 resultats trouvés
B
Berliere J-M.  2021.  Between yesterday occupied and tomorrow ``liberated''. The consequences of the period 1940-1944 on the French police and police society. HISPANIA NOVA. :661-690.
Ghalmane Z, Hassouni MEl, Cherifi H.  2018.  Betweenness Centrality for Networks with Non-Overlapping Community Structure. 2018 IEEE WORKSHOP ON COMPLEXITY IN ENGINEERING (COMPENG 2018).
Ghalmane Z, Hassouni MEl, Cherifi H.  2018.  Betweenness Centrality for Networks with Non-Overlapping Community Structure. 2018 IEEE WORKSHOP ON COMPLEXITY IN ENGINEERING (COMPENG 2018).
Pierga J-Y, Delva R, Pivot X, Espie M, Dalenc F, Serin D, Veyret C, Lortholary A, Gligorov J, Joly K et al..  2014.  Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France. BULLETIN DU CANCER. 101:780-788.
Andre T., Vernerey D., Im S.-A, Bodoky G.M, Buzzoni R., Reingold S., Rivera F., McKendrick J., Scheithauer W., Geva R. et al..  2019.  Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group. ANNALS OF ONCOLOGY. 30
Andre T., Vernerey D., Im S.A, Bodoky G., Buzzoni R., Reingold S., Rivera F., McKendrick J., Scheithauer W., Ravit G. et al..  2020.  Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. ANNALS OF ONCOLOGY. 31:246-256.
Salvatore L, Bria E, Sperduti I, Hinke A, Hegewisch-Becker S, Aparicio T, Le Malicot K, Boige V, Koeberle D, Baertschi D et al..  2021.  Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. CANCER TREATMENT REVIEWS. 97:102202.
Bennouna J., Hiret S., Borg C., Bertaut A., Bouche O., Deplanque G., Francois E., Conroy T., Ghiringhelli F., G. Guetz D et al..  2017.  Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI. ANNALS OF ONCOLOGY. 28
Bennouna J., Hiret S., Borg C., Bertaut A., Bouche O., Deplanque G., Francois E., Conroy T., Ghiringhelli F., G. Guetz D et al..  2017.  Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI. ANNALS OF ONCOLOGY. 28
Mineur L., Francois E., Kim S., Burki F., Laplaige P., Gourgou S., Rollot-Trad F., Telliez J., Gandon S., Smith D..  2016.  Bevacizumab combined with 1st line chemotherapy in elderly patients (>= 75 years-old) with metastatic colorectal cancer - Interim results according to the chemotherapy regimen (CASSIOPEE). ANNALS OF ONCOLOGY. 27
Bennouna J., Falchero L., Schott R., Bonnetain F., Coudert M., B. Yahia BHadj, Chouaid C..  2017.  Bevacizumab Combined with Chemotherapy for Patients with Advanced NSCLC and Brain Metastasis. A French Cohort Study. JOURNAL OF THORACIC ONCOLOGY. 12:S1808.
Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z et al..  2014.  Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection. ANNALS OF SURGICAL ONCOLOGY. 21:1632-1640.
Chouaid C., Falchero L., Schott R., Bonnetain F., Taguieva-Pioger N., Bennouna J..  2017.  Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study. REVUE DES MALADIES RESPIRATOIRES. 34:36-43.
Bennouna J, Falchero L, Schott R, Bonnetain F, Coudert M, Yahia BBen Hadj, Chouaid C.  2018.  Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE). ONCOLOGY. 94:55-64.
Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bennouna J.  2018.  Bevacizumab Maintenance in Metastatic Colorectal Cancer Reply. JOURNAL OF CLINICAL ONCOLOGY. 36:2452+.
Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouche O, Phelip J-M, Francois E, Borel C, Faroux R et al..  2018.  Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). JOURNAL OF CLINICAL ONCOLOGY. 36:674+.
Hiret S, Borg C, Bertaut A, Bouche O, Adenis A, Deplanque G, Francois E, Conroy T, Ghiringhelli F, Guetz GDes et al..  2016.  Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18-UNICANCER GI).. JOURNAL OF CLINICAL ONCOLOGY. 34
Caulet M, Lecomte T, Bouche O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Leger J, Borg C, Douillard J-Y, Manfredi S et al..  2016.  Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. CLINICAL PHARMACOKINETICS. 55:1381-1394.
von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E et al..  2014.  Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised. LANCET ONCOLOGY. 15:1269-1278.
Aparicio T., Bouche O., Taieb J., Maillard E., Kirscher S., Etienne P.-L, Faroux R., F. Akouz K, F. Hajbi E, Locher C. et al..  2018.  Bevacizumab plus chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. ANNALS OF ONCOLOGY. 29:133-138.
de Gramont A., Henriques J., Baruch B., Kim T.W, Martinez-Villacampa M., Gallego-Plazas J., Cervantes A., Shim K., Jonker D.J, Guerin-Meyer V. et al..  2019.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group. ANNALS OF ONCOLOGY. 30
de Gramont A., Henriques J., Baruch B., Kim T.W, Martinez-Villacampa M., Gallego-Plazas J., Cervantes A., Shim K., Jonker D.J, Guerin-Meyer V. et al..  2019.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group. ANNALS OF ONCOLOGY. 30
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mesange P, Lledo G, Viret F, Ramee J-F, Tubiana-Mathieu N et al..  2015.  Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. LANCET ONCOLOGY. 16:1493-1505.
Collot T, Fumet J-D, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F.  2018.  Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors. ANTICANCER RESEARCH. 38:5963-5968.
Legal J-B, Chekroun P, Coiffard V, Gabarrot F.  2017.  Beware of the gorilla: Effect of goal priming on inattentional blindness. CONSCIOUSNESS AND COGNITION. 55:165-171.

Pages